Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Committee calls for GM insects
Grasshopper
The technology is believed to have the potential to help control diseases such as dengue and malaria.

Technology may have potential to help control diseases and pests

The House of Lords are calling on the Government to launch a field trial of genetically modified (GM) insects and make the most of the UK's status as a world leader in this area.

The technology is believed to have the potential to help control diseases such as dengue and malaria, by rendering insects unable to transmit disease.  This could potentially help almost half of the global population, who live in at-risk areas.

It is thought that GM technology could also reduce insect populations to minimise their threat to animals and crops, saving the world billions of pounds in the process.  

The call follows the publication of a report by the House of Lords Science and Technology Committee into Genetically Modified insects. In it, they state that GM insects have considerable potential to control insect-borne disease and agricultural pests, but they are no 'silver bullet'.

The report describes how the UK, a world leader in this area of research, could reap significant economic benefits. However, it says that EU regulation is 'failing lamentably'.

Commenting on the report, the Earl of Selborne, chairman of the House of Lords Science and Technology Committee, explains:

"GM insect technologies have the potential not only to save countless lives worldwide, but also to generate significant economic benefits for UK plc, where we are an acknowledged world leader. But the development of GM insect technologies has come to a screeching halt because the EU regulatory system is woefully inadequate. Until we can get a regulatory framework that will do justice to this area of scientific research, its wings are effectively clipped.

"Our report concludes that the UK Government has a moral duty to test the potential of this technology, for the long-term benefit of those countries where diseases like dengue and malaria are indiscriminate killers. So as a first step towards that goal, we urge the Government to initiate field trials to put not only the science but, crucially, the regulations to the test. This trial could also be a focus to increase public engagement in the area."

Become a member or log in to add this story to your CPD history

Greyhound Board announces change to vaccination guidance

News Story 1
 The Greyhound Board of Great Britain has published new vaccination guidance, with all greyhounds registered from 1 January, 2027 required to have the L4 leptospirosis vaccination, rather than L2.

The change comes in response to the reduced availability of the 'L2' Leptospirosis vaccine across the UK, and aims to support best biosecurity practice across the racing greyhound population.

GBGB veterinary director Simon Gower, said "While rare, Leptospirosis is a serious infectious disease that can affect both dogs and humans, so it is vital that we offer our greyhounds the broadest possible protection.  

Click here for more...
News Shorts
Free webinar explores congenital heart disease in dogs

A free webinar is to provide veterinary professionals, dog breeders and pet owners an new insights into congenital heart disease.

Chris Linney, a cardiology specialist and Veterinary Cardiovascular Society (VSC) member, will present the webinar from 7.00pm to 8.30pm on Wednesday, 12 November.

Dr Linney will explore the types, causes and clinical presentation of congenital heart conditions. This will include diagnostic approaches, treatment pathways and emerging research opportunities.

The session is the third to be organised by The Kennel Club, with the VCS, following an introductory webinar and a talk on acquired heart disease. Dr Linney's webinar consists of a one-hour presentation, followed by a 30-minute question and answer session.

Dr Linney said: "This webinar will be an opportunity to deepen understanding - not just of the diseases themselves, but of how breeders, vets and owners can work together to support affected dogs and improve outcomes for future generations."

Click here to register for the webinar.